191 related articles for article (PubMed ID: 19285071)
1. Edaravone in ALS.
Takahashi R
Exp Neurol; 2009 Jun; 217(2):235-6. PubMed ID: 19285071
[No Abstract] [Full Text] [Related]
2. Drug therapy: On the treatment trail for ALS.
Scott A
Nature; 2017 Oct; 550(7676):S120-S121. PubMed ID: 29045376
[No Abstract] [Full Text] [Related]
3. Edaravone (Radicava) for ALS.
Med Lett Drugs Ther; 2017 Nov; 59(1533):180-182. PubMed ID: 29125592
[No Abstract] [Full Text] [Related]
4. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger.
Aoki M; Warita H; Mizuno H; Suzuki N; Yuki S; Itoyama Y
Brain Res; 2011 Mar; 1382():321-5. PubMed ID: 21276427
[TBL] [Abstract][Full Text] [Related]
5. Edaravone and its clinical development for amyotrophic lateral sclerosis.
Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
[TBL] [Abstract][Full Text] [Related]
6. Is erythropoietin a potential therapy for amyotrophic lateral sclerosis?
Butsch PO; Cudkowicz ME
Exp Neurol; 2007 Jul; 206(1):11-5. PubMed ID: 17498699
[No Abstract] [Full Text] [Related]
7. Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis.
Shin JH; Lee YA; Lee JK; Lee YB; Cho W; Im DS; Lee JH; Yun BS; Springer JE; Gwag BJ
J Neurochem; 2012 Sep; 122(5):952-61. PubMed ID: 22537108
[TBL] [Abstract][Full Text] [Related]
8. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R; Kuhad A; Kuhad A
Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
[TBL] [Abstract][Full Text] [Related]
9. Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA.
Wang J; Xu G; Slunt HH; Gonzales V; Coonfield M; Fromholt D; Copeland NG; Jenkins NA; Borchelt DR
Neurobiol Dis; 2005 Dec; 20(3):943-52. PubMed ID: 16046140
[TBL] [Abstract][Full Text] [Related]
10. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.
Nagase M; Yamamoto Y; Miyazaki Y; Yoshino H
Redox Rep; 2016 May; 21(3):104-12. PubMed ID: 26191780
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.
Sawada H
Expert Opin Pharmacother; 2017 May; 18(7):735-738. PubMed ID: 28406335
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target.
Barber SC; Shaw PJ
Free Radic Biol Med; 2010 Mar; 48(5):629-41. PubMed ID: 19969067
[TBL] [Abstract][Full Text] [Related]
13. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
Ikeda K; Iwasaki Y
PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
[TBL] [Abstract][Full Text] [Related]
14. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice.
Ito H; Wate R; Zhang J; Ohnishi S; Kaneko S; Ito H; Nakano S; Kusaka H
Exp Neurol; 2008 Oct; 213(2):448-55. PubMed ID: 18718468
[TBL] [Abstract][Full Text] [Related]
15. Superoxide dismutase: the cause of all amyotrophic lateral sclerosis?
Matias-Guiu J; Galan L; Garcia-Ramos R; Barcia JA
Ann Neurol; 2008 Sep; 64(3):356-7; author reply 358. PubMed ID: 18350588
[No Abstract] [Full Text] [Related]
16. What can we learn from the edaravone development program for ALS?
Maragakis NJ
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):98-103. PubMed ID: 28872911
[TBL] [Abstract][Full Text] [Related]
17. July 2017 ENCALS statement on edaravone.
Al-Chalabi A; Andersen PM; Chandran S; Chio A; Corcia P; Couratier P; Danielsson O; de Carvalho M; Desnuelle C; Grehl T; Grosskreutz J; Holmøy T; Ingre C; Karlsborg M; Kleveland G; Koch JC; Koritnik B; KuzmaKozakiewicz M; Laaksovirta H; Ludolph A; McDermott C; Meyer T; Mitre Ropero B; Mora Pardina J; Nygren I; Petri S; Povedano Panades M; Salachas F; Shaw P; Silani V; Staaf G; Svenstrup K; Talbot K; Tysnes OB; Van Damme P; van der Kooi A; Weber M; Weydt P; Wolf J; Hardiman O; van den Berg LH
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Nov; 18(7-8):471-474. PubMed ID: 28975816
[No Abstract] [Full Text] [Related]
18. Has gene therapy for ALS arrived?
Miller TM; Cleveland DW
Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369
[No Abstract] [Full Text] [Related]
19. Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis.
Chang-Hong R; Wada M; Koyama S; Kimura H; Arawaka S; Kawanami T; Kurita K; Kadoya T; Aoki M; Itoyama Y; Kato T
Exp Neurol; 2005 Jul; 194(1):203-11. PubMed ID: 15899257
[TBL] [Abstract][Full Text] [Related]
20. Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS.
Robertson J; Sanelli T; Xiao S; Yang W; Horne P; Hammond R; Pioro EP; Strong MJ
Neurosci Lett; 2007 Jun; 420(2):128-32. PubMed ID: 17543992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
